DDInter1200 DDInter1376
Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succinate derivative. To this date, it is one of the preferred beta-blockers in general clinical guidelines and it is widely prescribed in the Netherlands, New Zealand, and the US. Metoprolol was developed since 1969 by US Pharmaceutical Holdings I and FDA approved in 1978.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Metoprolol {u} (Compound) resembles {v} (Compound) Oxprenolol
Metoprolol {u} (Compound) resembles {v} (Compound) Metipranolol
Metoprolol {u} (Compound) treats {v} (Disease) hypertension
Metoprolol {u} (Compound) binds {v} (Gene) SLC22A2
Metoprolol {u} (Compound) upregulates {v} (Gene) HOOK2
Metoprolol {u} (Compound) downregulates {v} (Gene) LAP3
Metoprolol {u} (Compound) causes {v} (Side Effect) Coma
Metoprolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Levothyroxine
Metoprolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glucagon
Metoprolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pasireotide
Metoprolol (Compound) resembles Oxprenolol (Compound)
Metoprolol (Compound) resembles Metipranolol (Compound)
Metoprolol (Compound) treats hypertension (Disease)
Metoprolol (Compound) binds SLC22A2 (Gene)
Metoprolol (Compound) upregulates HOOK2 (Gene)
Metoprolol (Compound) downregulates LAP3 (Gene)
Metoprolol (Compound) causes Coma (Side Effect)
Metoprolol may cause a minor interaction that can limit clinical effects when taken with Levothyroxine
Metoprolol may cause a minor interaction that can limit clinical effects when taken with Glucagon
Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide